{"id":44785,"date":"2012-05-16T03:12:37","date_gmt":"2012-05-16T03:12:37","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/axiomed-spine-corporation-receives-ce-mark-for-freedom-cervical-disc.php"},"modified":"2012-05-16T03:12:37","modified_gmt":"2012-05-16T03:12:37","slug":"axiomed-spine-corporation-receives-ce-mark-for-freedom-cervical-disc","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/freedom\/axiomed-spine-corporation-receives-ce-mark-for-freedom-cervical-disc.php","title":{"rendered":"AxioMed Spine Corporation Receives CE Mark for Freedom\u00ae Cervical Disc"},"content":{"rendered":"<p><p>    GARFIELD HEIGHTS, Ohio--(BUSINESS WIRE)--  <\/p>\n<p>    AxioMed Spine Corporation    (www.axiomed.com)    announces the receipt of CE Mark approval for its    FreedomCervical Disc, an elastomeric total    spinal disc replacement device. The CE Mark approval was    received as a result of an accredited European Notified Body    conformity assessment of the Companys complete portfolio of    biocompatibility and biomechanical cervical disc testing and    supporting data regarding the Freedom technology.    AxioMeds first product was the FreedomLumbar Disc which    received CE Mark in 2009. The CE Mark clears AxioMed for the    introduction of the Freedom Cervical Disc into the    EU Market. AxioMed is an ISO 13485:2003 certified manufacturer    of the Freedom Lumbar and Cervical Discs.  <\/p>\n<p>    Patrick McBrayer, AxioMeds President and CEO stated, With the    Freedom Lumbar and Cervical Discs now both CE    Marked, we will be able to provide a complete next generation    elastomeric disc product line for patients and surgeons in the    EU. Our EU lumbar clinical data, published in peer reviewed    spine journals, demonstrate that Freedom technology has been shown to    provide patients pain relief, reduced disability and improved    lifestyle, based on monitored outcomes and feedback. We are    also active in our multi-center pivotal clinical study under an    Investigational Device Exemption for our Freedom Lumbar Disc    with both efficacy and economic endpoints. Our goal is to have    the most advanced and complete total disc product line in the    US and EU.  <\/p>\n<p>    Jim Kuras, the Companys Chief Operating Officer added, The    Freedom Cervical Disc was developed by an    experienced team of surgeons and engineers, taking advantage of    the attributes of the lumbar technology and advancing the    technology platform into the cervical spine. The cervical    discs unique asymmetrical design and biomechanics evolve    beyond first generation total disc technologies, better    accommodating the cervical anatomy and spinal function.    Complementing the differentiated design, multiple footprints    and heights with wedge angles provide the surgeon with an array    of implants to address the patient specific surgical    requirements.  <\/p>\n<p>    Neal Defibaugh, AxioMeds Vice President of Clinical and    Regulatory Affairs, went on to comment, AxioMeds extensive    pre-clinical and clinical experience with the    Freedom technology was instrumental in providing a    solid regulatory foundation for achieving a CE Mark approval on    our Freedom Cervical Disc. We have leveraged our    Freedom technology for the cervical disc regulatory pathway and    timing in obtaining the CE Mark and we anticipate a similar    advantage for our future US FDA IDE approval efforts.  <\/p>\n<p>    The Freedom Cervical Disc is a viscoelastic    one-piece, next generation total disc replacement featuring a    polymer core, designed with the goal of restoring function of    the spine and reducing pain and disability. CE Mark approval    allows for the commercial distribution of the Freedom Cervical    Disc throughout the European Union. AxioMeds    Freedom Lumbar Disc has also attained a CE Mark, is    commercially available in select countries in the EU and is    under evaluation in an ongoing multi-center US and EU IDE    pivotal clinical study designed with efficacy, safety and    economic endpoints.  <\/p>\n<p>    About AxioMedSpine Corporation  <\/p>\n<p>    AxioMeds mission is to develop products focused on spinal    function for patients with degenerative spine disease, thus    advancing the standard of care beyond fusion and first    generation discs. The Freedom Lumbar and Cervical    Discs have been developed and designed by a team of clinicians    and experts in the fields of biomechanics, pathology, spinal    surgery and polymer science. Focusing on restoration of the    natural function of the spine, AxioMed will enhance human    health through research, innovation, development and service    world-wide. For more information about AxioMed, please visit    our web site at     <a href=\"http:\/\/www.axiomed.com\" rel=\"nofollow\">http:\/\/www.axiomed.com<\/a>.  <\/p>\n<\/p>\n<p>Go here to read the rest:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/axiomed-spine-corporation-receives-ce-130400452.html;_ylt=A2KJjbwZG7NP5AoADnz_wgt.\" title=\"AxioMed Spine Corporation Receives CE Mark for Freedom\u00ae Cervical Disc\">AxioMed Spine Corporation Receives CE Mark for Freedom\u00ae Cervical Disc<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> GARFIELD HEIGHTS, Ohio--(BUSINESS WIRE)-- AxioMed Spine Corporation (www.axiomed.com) announces the receipt of CE Mark approval for its FreedomCervical Disc, an elastomeric total spinal disc replacement device. The CE Mark approval was received as a result of an accredited European Notified Body conformity assessment of the Companys complete portfolio of biocompatibility and biomechanical cervical disc testing and supporting data regarding the Freedom technology <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/freedom\/axiomed-spine-corporation-receives-ce-mark-for-freedom-cervical-disc.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[30],"tags":[],"class_list":["post-44785","post","type-post","status-publish","format-standard","hentry","category-freedom"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/44785"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=44785"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/44785\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=44785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=44785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=44785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}